How is bosutinib progressing in the treatment of ALS?

Bosutinib (Bosutinib) is showing some promise in treating amyotrophic lateral sclerosis (ALS). Although bosutinib was originally developed as a drug to treat chronic myelogenous leukemia (CML), recent studies have shown that it may also have some therapeutic effect in ALS.

The current research on bosutinib in the treatment of ALS is still in its preliminary stage, and more clinical trials and in-depth research are needed to confirm its efficacy and safety. Some studies have shown that bosutinib can inhibit oxidative stress and reduce nerve cell damage, thereby achieving the effect of protecting nerve cells. In addition, it can promote the growth of neurons, improve neurological function, and improve patients' quality of life. In a pilot study involving nine ALS patients, five patients' condition did not worsen after about three months of treatment with bosutinib, while four others' condition worsened at the same rate as before taking the drug. This suggests that bosutinib may have some effect in slowing the progression of the disease, but not all patients will respond to the drug.

The originator drug of bosutinib is not marketed in the country, so it cannot be included in medical insurance. Currently, the original drugs sold overseas include Turkish version and European version. The price of the Turkish version may be more than RMB 2,000 per box of 500mg*28, and the price of the European version may be more than RMB 30,000 (the price may fluctuate due to the exchange rate). There are also bosutinib generic drugs produced overseas in other countries. Their pharmaceutical ingredients are basically the same as those of the original drug. The price of 500mg*30 per box may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.